Author Correction: Transitions from Ideal to Intermediate Cholesterol Levels may vary by Cholesterol Metric

Autor: Joseph C. Engeda, Katelyn M. Holliday, Shakia T. Hardy, Sujatro Chakladar, Dan-Yu Lin, Gregory A. Talavera, Barbara V. Howard, Martha L. Daviglus, Amber Pirzada, Pamela J. Schreiner, Donglin Zeng, Christy L. Avery

Publikováno v: Scientific Reports, Vol 8, Iss 1, Pp 1-2 (2018)

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper

Externí odkaz: https://doaj.org/article/3e3e83d3716f4bff96d8e96d9ec12484

Win ratio approach for analyzing composite time‐to‐event endpoint with opposite treatment effects in its components

Autor: Ran Liao, Sujatro Chakladar, Margaret Gamalo

Publikováno v: Pharmaceutical Statistics. 21:1342-1356

There is an increasing interest in the use of win ratio with composite time-to-event due to its flexibility in combining component endpoints. Exploring this flexibility further, one interesting question is in assessing the impact when there is a diff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::552f26a5d9f447cf7aa21018a4d2c704
https://doi.org/10.1002/pst.2248

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Autor: E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, Stephanie de Bono, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, José Francisco Kerr Saraiva, Sujatro Chakladar, Vincent C Marconi, Jorge Alatorre-Alexander, Javier David Altclas, Marcelo Casas, Valeria CevoliRecio, Todd Ellerin, Kleber Giovanni Luz, Jason D. Goldman, Maria Patelli Juliani Souza Lima, Akram Khan, Priscila Paulin, Ana Carolina Procopio Carvalho, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Imad Shawa, Jesus Simon Campos, Brian Tiffany, Adilson Westheimer Cavalcante

Publikováno v: The Lancet. Respiratory Medicine

Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of ba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2df8fedd601de59cb1895fd3b9fbf90c
https://pubmed.ncbi.nlm.nih.gov/35667076

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Autor: Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely, Mi-Young Ahn, Miriam Akasbi, Javier David Altclas, Federico Ariel, Horacio Alberto Ariza, Chandrasekhar Atkar, Anselmo Bertetti, Meenakshi Bhattacharya, Maria Luisa Briones, Akshay Budhraja, Aaliya Burza, Adrian Camacho Ortiz, Roberto Caricchio, Marcelo Casas, Valeria Cevoli Recio, Won Suk Choi, Emilia Cohen, Angel Comulada-Rivera, Paul Cook, Dora Patricia Cornejo Juarez, Carnevali Daniel, Luiz Fernando Degrecci Relvas, Jose Guillermo Dominguez Cherit, Todd Ellerin, Dmitry Enikeev, Suzana Erico Tanni Minamoto, Elie Fiss, Motohiko Furuichi, Kleber Giovanni Luz, Jason D. Goldman, Omar Gonzalez, Ivan Gordeev, Thomas Gruenewald, Victor Augusto Hamamoto Sato, Eun Young Heo, Jung Yeon Heo, Maria Hermida, Yuji Hirai, David Hutchinson, Claudio Iastrebner, Octavian Ioachimescu, Manish Jain, Maria Patelli Juliani Souza Lima, Akram Khan, Andreas E. Kremer, Thomas Lawrie, Mark MacElwee, Farah Madhani-Lovely, Vinay Malhotra, Michel Fernando Martínez Resendez, James McKinnell, Patrick Milligan, Cesar Minelli, Miguel Angel Moran Rodriguez, Maria Leonor Parody, Priscila Paulin, Priscilla Pemu, Ana Carolina Procopio Carvalho, Massimo Puoti, Joshua Purow, Mayur Ramesh, Alvaro Rea Neto, Philip Robinson, Cristhieni Rodrigues, Gustavo Rojas Velasco, Jose Francisco Kerr Saraiva, Morton Scheinberg, Stefan Schreiber, Dario Scublinsky, Anete Sevciovic Grumach, Imad Shawa, Jesus Simon Campos, Nidhi Sofat, Christoph D. Spinner, Eduardo Sprinz, Roger Stienecker, Jose Suarez, Natsuo Tachikawa, Hasan Tahir, Brian Tiffany, Alexander Vishnevsky, Adilson Westheimer Cavalcante, Kapil Zirpe

Publikováno v: The Lancet. Respiratory Medicine

Summary Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf64edd09bbf67d7978734149d4c838a
http://europepmc.org/articles/PMC8409066

Inverse Probability Weighted Estimators of Vaccine Effects Accommodating Partial Interference and Censoring

Autor: Michael Emch, Mohammad Ali, Samuel Rosin, Michael G. Hudgens, Sujatro Chakladar, John D. Clemens, M. Elizabeth Halloran

Publikováno v: Biometrics

Estimating population-level effects of a vaccine is challenging because there may be interference, i.e., the outcome of one individual may depend on the vaccination status of another individual. Partial interference occurs when individuals can be par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dc71520e4846c35b56ff54c71b5139
https://europepmc.org/articles/PMC8463630/